
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Overview
Explore Rhythm Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Rhythm Pharmaceuticals, Inc. (RYTM)
Key Financials
Key Financials
Market Cap
7.3B
P/E Ratio
-34.04
EPS (TTM)
$-3.13
ROE
-2.01%
RYTM Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Rhythm Pharmaceuticals, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of RYTM on the NASDAQ shows an RSI of 51.99, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $130.23 for the NASDAQ listing.
Key metrics behind Rhythm Pharmaceuticals, Inc.'s NASDAQ-traded stock include a P/E ratio of -34.04 and a market capitalization of 7.3B. Combined with our AI analysis, these give both institutional and retail investors a clear view of RYTM on the NASDAQ.